Achromatopsia
Achromatopsia is a rare inherited retinal disease that affects the cone photoreceptor cells of the retina, resulting in reduced or absent colour vision and significant sensitivity to light.
Understanding Achromatopsia
Achromatopsia is a rare inherited retinal disease that affects the cone cells in the retina, which are responsible for colour vision and seeing detail in bright light.
People with achromatopsia typically have complete or partial colour blindness, reduced vision, and strong sensitivity to light (photophobia). Symptoms are usually present from birth or early childhood and can make bright environments difficult to see in.
There is currently no cure, but advances in genetic research and emerging treatments are helping researchers better understand achromatopsia and explore new treatment options.
Retina International works with people affected by achromatopsia, patient organisations, researchers, and clinicians worldwide to support research and improve diagnosis, care, and quality of life.
What is Achromatopsia?
Achromatopsia is an inherited retinal disease caused by dysfunction or absence of cone photoreceptor activity in the retina.
The retina contains two main types of photoreceptor cells:
- Cone cells – responsible for colour vision, sharp central vision, and seeing in bright light.
- Rod cells – responsible for vision in low light and peripheral vision.
In achromatopsia, cone cells do not function properly, meaning the retina cannot process colour information normally.
The condition is usually present from birth or early childhood. Unlike progressive retinal diseases where vision declines over time, many people with achromatopsia have a relatively stable level of visual impairment throughout life, although some individuals may experience changes over time.
Achromatopsia is sometimes referred to as:
- Complete achromatopsia
- Total colour blindness
- Rod monochromacy
The condition is rare and affects people worldwide.
Diagnosis
Genetic testing can help identify the specific genetic cause
Symptoms
Symptoms usually appear in infancy or early childhood
Gene therapy
Researchers are investigating whether delivering functional copies of affected genes can restore cone cell activity
How Achromatopsia can affect vision
Reduced or absent colour vision
People with achromatopsia may see the world mainly in shades of grey or have severely reduced ability to distinguish colours.
Light sensitivity (photophobia)
Extreme sensitivity to bright light is one of the most common features of achromatopsia.
Bright environments may cause discomfort and make it difficult to see clearly.
Reduced visual acuity
Many people have reduced sharpness of vision, particularly in bright conditions.
Nystagmus
Some individuals experience involuntary eye movements, especially during infancy.
Difficulty seeing in bright environments
Vision may improve in dim lighting because rod cells remain functional.
Reduced ability to see fine details
Reading, recognising faces, and tasks requiring detailed vision may be challenging.
Symptoms and severity can vary depending on the genetic cause and level of cone function remaining.
Identifying Achromatopsia
Eye examination
An ophthalmologist evaluates visual function and examines the retina.
Visual acuity testing
This measures the clarity of vision and helps assess the impact of reduced cone function.
Colour vision testing
Specialised tests assess the ability to perceive and distinguish colours.
Electroretino-graphy (ERG)
An ERG evaluates retinal function by measuring electrical responses from photoreceptor cells.
In achromatopsia, cone responses are typically reduced or absent.
Optical coherence tomography (OCT)
OCT imaging provides detailed images of retinal layers and may identify changes in cone-related areas.
Genetic testing
Genetic testing can identify the gene responsible for achromatopsia and confirm diagnosis.
A genetic diagnosis can support:
- Understanding inheritance
- Accessing clinical research
- Future treatment planning
- Family decisions
Current approaches to managing Achromatopsia
Managing light sensitivity
Approaches may include:
- Tinted lenses
- Specialised sunglasses
- Adaptive lighting environments
- Glare reduction strategies
Low vision support
Specialist services can provide:
- Magnification tools
- Assistive technology
- Digital accessibility tools
- Reading support
Educational and workplace support
Children and adults may benefit from:
- Classroom adaptations
- Accessible materials
- Workplace adjustments
- Assistive devices
Vision rehabilitation
Rehabilitation can support:
- Independent living
- Mobility
- Confidence in daily activities
Emerging treatments
Research is exploring therapies that aim to restore cone function, including:
- Gene therapy
- Gene-based treatments
- Retinal cell therapies
Adapting to life with reduced colour vision and light sensitivity
Achromatopsia can affect how people see and interact with the world, but with the right support and adaptations, many people take part fully in education, work, relationships, and daily life.
Support may include:
- Low vision services
- Assistive technology
- Accessible environments
- Patient organisations and peer support
Common challenges can include bright environments, reading standard print, recognising visual information, and accessing information that relies on colour.
Understanding and appropriate support from schools, workplaces, and communities can help people with achromatopsia live independently. The experiences of people living with the condition are also important in shaping better care, accessibility, and research.
Advancing the future of Achromatopsia treatment
Gene therapy
Researchers are investigating whether delivering functional copies of affected genes can restore cone cell activity.
Gene therapy approaches have focused particularly on:
- CNGA3-associated achromatopsia
- CNGB3-associated achromatopsia
Retinal imaging advances
Advanced imaging techniques allow researchers to study cone structure and monitor changes over time.
Learn About Retinal ImagingNatural history studies and registries
Research studies track how achromatopsia affects vision over time and help identify meaningful outcomes for clinical trials.
Learn About Natural History StudiesClinical trials
Clinical studies are investigating potential treatments aimed at restoring or improving cone function.
Participation from people living with achromatopsia is essential for:
- Understanding the condition
- Developing meaningful treatments
- Designing patient-centred clinical trials
Information and community support
Take the Next Step
Achromatopsia demonstrates the importance of understanding genetic causes of retinal conditions and developing targeted approaches that address specific changes affecting vision.
Through collaboration between patients, researchers, clinicians, and organisations worldwide, progress continues towards improved support, innovative therapies, and a future where people affected by inherited retinal diseases have more opportunities to preserve and restore vision.
